MIRM - Mirum Pharmaceuticals GAAP EPS of -$0.54 misses by $0.14 revenue of $69.2M misses by $0.97M
2024-05-08 17:07:42 ET
More on Mirum Pharmaceuticals
- Mirum Pharmaceuticals: After Phase 2 Miss, An iBAT Inhibitor On Deck To Drive Value
- Mirum Pharmaceuticals: Advancing On Several Key Fronts
- Mirum Pharmaceuticals, Inc. (MIRM) Q4 2023 Earnings Call Transcript
- Mirum Pharmaceuticals Q1 2024 Earnings Preview
- Stifel starts Mirum at buy, cites IBATi drug potential